Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
Patients with metastatic hormone refractory prostate cancer (HRPC) have limited treatment options and new therapies are needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets including Bcl-2, an important pro-survival regulator of apoptotic cell death. Bcl-2 is overexpressed in a variety of human malignancies including prostate cancer where it has also been associated with androgen independent progression and treatment resistance. Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy. Clinical trials evaluating oblimersen in combination with chemotherapy in a variety of cancers have shown good tolerability and promising response rates. Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC.
Chi
Kim N
KN
BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada. kchi@bccancer.bc.ca
D017209:Apoptosis / Q000187:drug effects; D018390:Gene Targeting / Q000379:methods*; D019254:Genes, bcl-2 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D013873:Thionucleotides / Q000627:therapeutic use*
D013873:Thionucleotides; C408162:oblimersen
Am J Pathol. 1993 Aug;143(2):390-400
7688182
Ann Oncol. 2001 Sep;12(9):1273-9
11697840
Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):133-4
9593052
Clin Cancer Res. 2002 Aug;8(8):2530-5
12171880
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
J Clin Oncol. 1999 Sep;17(9):2941-53
10561374
Proc Natl Acad Sci U S A. 1978 Jan;75(1):280-4
75545
J Pharmacol Exp Ther. 2001 Sep;298(3):934-40
11504787
Cancer Res. 1995 Oct 1;55(19):4438-45
7671257
Am J Pathol. 1996 May;148(5):1557-65
8623924
Breast Cancer Res Treat. 2000 Oct;63(3):199-212
11110054
Cancer Res. 1999 Aug 15;59(16):4030-4
10463603
J Urol. 1999 Jul;162(1):12-6; discussion 16-7
10379729
J Natl Cancer Inst. 2000 Jan 5;92(1):34-41
10620631
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
J Clin Oncol. 1999 Aug;17(8):2506-13
10561316
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002
9560217
Cancer Res. 1999 Nov 1;59(21):5429-32
10554011
J Clin Oncol. 1996 Jun;14(6):1756-64
8656243
Cell Death Differ. 1998 May;5(5):372-80
10200486
Clin Cancer Res. 2001 Dec;7(12):3920-7
11751483
Cancer Res. 1992 Dec 15;52(24):6940-4
1458483
Clin Cancer Res. 2002 Mar;8(3):679-83
11895895
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
15173273
Nat Med. 1998 Feb;4(2):232-4
9461199
Cancer Res. 1997 Jan 15;57(2):229-33
9000560
J Clin Oncol. 2000 May;18(9):1812-23
10784621
Nature. 1997 Jun 19;387(6635):773-6
9194558
Cell. 1997 Nov 28;91(5):559-62
9393848
Clin Cancer Res. 2001 Aug;7(8):2537-44
11489837
Clin Cancer Res. 2000 Jul;6(7):2891-902
10914739
Clin Cancer Res. 2000 Jun;6(6):2492-500
10873104
Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213
12162702
Proc Natl Acad Sci U S A. 1977 Oct;74(10):4370-4
270678
Br J Cancer. 1998 Oct;78(8):1035-42
9792147
J Urol. 1997 Feb;157(2):569-74
8996359
Int J Cancer. 2001 Mar 15;91(6):846-50
11275990